Work

Folate-functionalized chitosan nanocarriers of an iron nitrosyl nitric oxide donor for dual antileukemic and antibacterial activity in acute myeloid leukemia cells

Year: 2026
Type: article
Abstract: Acute myeloid leukemia (AML) treatment is frequently complicated by severe bacterial infections resulting from chemotherapy-induced neutropenia, creating a need for therapeutic platforms that address both leukemic progression and infection-related complications. In this study, folate-functionalized chitosan nanocarriers loaded with an iron nitrosyl nitric oxide donor, FA-CS@FeNOTSP, were developed as a dual-action platform for antileukemic and antibacterial evaluation. The nanocarriers were obtained by carbodiimide-mediated folate conjugation followed by FeNOTSP encapsulation and characterized by FT-IR, UV–Vis spectroscopy, zeta-potential analysis, scanning electron microscopy, and dynamic light scattering. FA-CS@FeNOTSP exhibited high encapsulation efficiency (approximately 85–92%), SEM-derived particle dimensions of approximately 210 nm, hydrodynamic diameters of approximately 250–327 nm in aqueous suspension, and a marked surface-charge shift consistent with folate functionalization. The formulation showed pH/GSH-responsive release, with limited FeNOTSP liberation under physiological conditions (approximately 20% at pH 7.4 after 24 h) and enhanced release under acidic, reductive conditions (approximately 40% at pH 4.5 with 10 mM GSH). DNA-binding and stopped-flow studies indicated moderate ctDNA interaction (K b = 4.31 × 10 4 M − 1 ) through a reversible two-step mechanism involving rapid electrostatic association followed by slower structural binding. FA-CS@FeNOTSP displayed low hemolytic activity (< 1%), reduced cytotoxicity toward WI38 fibroblasts (IC 50 =162.07 ± 1.89 µg mL − 1 ), retained activity against Kasumi-1 AML cells (IC 50 = 84.99 ± 1.11 µg mL − 1 ), and exerted broad-spectrum antibacterial effects (21–32 mm inhibition zones, comparable to gentamicin). Pre-exposure of Kasumi-1 cells to excess free folic acid increased the IC 50 of FA-CS@FeNOTSP by 35.4%, providing preliminary functional support for the contribution of folate-sensitive cellular interactions to the in-vitro response. Collectively, these findings support FA-CS@FeNOTSP as an in-vitro proof-of-concept multifunctional platform with responsive release, antileukemic activity, and antibacterial effects.
Language: English
Subfield: Biomaterials
Open Access status: gold
Estimated APC paid: $2,690
OpenAlex ID: W7235969794
FWCI:
Cites: 43
Cited by:
Related to: 10